Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CREB3L2
REST API REST API
Homo sapiens
CREB3L2 is differentially expressed in 307 experiments: 158 organism parts: brain, cerebellum, ... (156 more);, 186 disease states: normal, Burkitt's lymphoma, ... (184 more);, 114 cell types 458 cell lines 37 compound treatments and 81 other conditions.
Synonyms TCAG_1951439, BBF2H7
Orthologs Creb3l2 (Rattus norvegicus)   CREB3L2 (Danio rerio)   F1P1J2_CHICK (Gallus gallus)   CREB3L2 (Bos taurus)   Creb3l2 (Mus musculus)   CrebA (Drosophila melanogaster)   CREB3L2 (Xenopus laevis)   CREB3L2 (Canis familiaris)   (Compare orthologs)
InterPro Term bZIP_1, bZIP_2, TF_bZIP
Gene Ontology Term endoplasmic reticulum, regulation of transcription, DNA-dependent, membrane, response to unfolded protein, sequence-specific DNA binding, protein dimerization activity, nucleus, integral to membrane, endoplasmic reticulum membrane, response to endoplasmic reticulum stress, positive regulation of transcription, DNA-dependent, ER to Golgi vesicle-mediated transport, chondrocyte differentiation, cartilage development, cAMP response element binding, sequence-specific DNA binding transcription factor activity, transcription regulatory region DNA binding
UniProt Accession Q86VD4, Q70SY1, C9JPH0, E7EPT7, F5H187
Search EB-eye ENSG00000182158
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, E-GEOD-7540, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529, E-GEOD-5823
BT20
2
E-MTAB-37, E-MTAB-62
AGS
2
E-MTAB-37, E-GEOD-15460
DU145
2
E-GEOD-17482, E-GEOD-20089
MOLT4
2
E-MTAB-37, E-MTAB-62
T84
2
E-GEOD-1474, E-MTAB-37
452 more value(s).


Cell type

studied in E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-TABM-34, E-GEOD-2822, ... (54 experiments)

Factor Value U/D Experiments
embryonic stem cell
2
E-GEOD-2248, E-MEXP-930
dendritic cell
2
E-MEXP-2019, E-GEOD-360
centroblast
2
E-TABM-702, E-GEOD-15271
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
keratinocyte
1
E-GEOD-3204
primary fibroblast
1
E-MEXP-66
108 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-1121, ... (63 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-1729, E-MTAB-62, E-GEOD-96
lung adenocarcinoma
3
E-MEXP-231, E-MTAB-62, E-GEOD-2514
prostate carcinoma
3
E-GEOD-96, E-MEXP-2034, E-MTAB-62
neuroblastoma
2
E-MTAB-37, E-MTAB-62
colon carcinoma
2
E-MTAB-62, E-MTAB-37
control
2
E-GEOD-21912, E-GEOD-16363
180 more value(s).


Compound treatment

studied in E-GEOD-5542, E-GEOD-1417, E-TABM-782, E-TABM-868, E-MEXP-1958, ... (25 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
none
4
5
E-MEXP-1958, E-GEOD-4600, E-TABM-782, E-TABM-868, E-MEXP-1230, ... (9 experiments)
AMP
1
1
E-MEXP-2285
Cxcl12
1
1
E-GEOD-7307
glucose
1
E-MEXP-941
heregulin
1
E-GEOD-6462
31 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-1140, E-GEOD-860, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-6207, E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (10 experiments)

Genotype
studied in E-GEOD-1045, E-TABM-1029, E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (12 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-GEOD-980

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-26495, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-GEOD-4600, ... (6 experiments)

Population
studied in E-GEOD-4922

Pr ihc
studied in E-GEOD-21653

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Qpcr egfr dct
studied in E-GEOD-5851

Replicate
studied in E-GEOD-17204

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

Processing time: 0.374 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM